The HIV Centers for Underrepresented Populations in Research Clinical Trials Unit (CURE CTU) will be comprised of five highly experienced and successful Clinical Research Sites (CRS) within the continental U.S. and a sixth new CRS located at Children?s National Medical Center in Washington, DC. Each of the CRSs has >20 years of experience conducting clinical research in pregnant women, infants, children, adolescents and young adults with and at-risk for HIV infection. Each of the HIV CURE CRSs is located in one of 48 counties or in Washington DC, geographic locations that have been targeted by the U.S. President?s initiative to end the HIV epidemic. The CURE CTU management is located at the University of California San Diego; Dr. Stephen A. Spector will serve as the Principal Investigator. The six CRSs are located at Baylor College of Medicine/Texas Children?s Hospital in Houston, TX, Ann & Robert H. Lurie Children?s Hospital of Chicago, IL, Northwestern University, St. Jude Children?s Research Hospital and the University of Tennessee Health Science Center in Memphis, TN, University of Miami, Holtz Children?s Hospital, Miami, FL, Children?s National Medical Center in Washington, DC, and the University of California, San Diego, CA. The CURE CTU is the only unit specifically focused on research in pregnant women, women, children, adolescents and young adults less than 25 years in the continental U.S. funded through NIAID.
The Specific Aims address many of the targeted high priority areas of the four NIAID proposed Networks.
Aim 1 : Identify novel and durable interventions to reduce reservoirs and control HIV replication in the absence of ART (ART- free remission) (ACTG Aim 1 and IMPAACT Aim 2).
Aim 2 : Advance ART of pregnant and postpartum women with HIV, to optimize maternal and infant health outcomes, and accelerate the evaluation (PK, safety, antiviral efficacy), licensure and optimal use of potent and durable ARVs for pregnant women, infants, children and adolescents with HIV (IMPAACT Aim 1).
Aim 3 : Design and conduct studies of broadly neutralizing antibodies (bnAbs), alone and in combination, and long-acting antiretroviral agents and delivery systems for pre-exposure prophylaxis (PrEP) (ACTG Aim 2, HPTN Aim 1, IMPAACT Aim 1).
Aim 4 : To investigate vaccination of HIV- exposed and unexposed infants to induce broad immune responses including broadly neutralizing antibody (HVTN Aim 4).
Specific Aim 5 : Design and conduct studies to evaluate multipurpose prevention technologies that concurrently prevent HIV and pregnancy, sexually transmitted infections or opioid dependence (HPTN Aim 2).
Aim 6 : Determine optimal and feasible methods for the prevention and management of complications and co-infections of HIV infection and their treatment in infants, children, adolescents and pregnant and postpartum women (IMPAACT Aim 4).
Aim 7 : Prevent or improve the treatment of HIV-related non-infectious co- morbidities and evaluate strategies to cure hepatitis B virus infection in people with/without HIV (ACTG Aim 4, HVTN Aim 1).

Public Health Relevance

The HIV Centers for Underrepresented Populations in Research Clinical Trials Unit (CURE CTU) will be comprised of six highly experienced research sites located at Texas Children?s Hospital, Baylor College of Medicine in Houston, TX, Ann & Robert H. Lurie Children?s Hospital of Chicago, IL, Northwestern University, St. Jude Children?s Research Hospital and the University of Tennessee Health Science Center in Memphis, TN, University of Miami, Holtz Children?s Hospital, Miami, FL, Children?s National Medical Center in Washington, DC, and the University of California, San Diego, CA; each located in an area targeted by the U.S. initiative to end the HIV epidemic. The CURE CTU is the only unit specifically focused on research in pregnant women, women, children, adolescents and young adults less than 25 years in the continental U.S. funded through NIAID. The Specific Aims of the CURE CTU address many of the targeted high priority areas of the 4 NIAID proposed Networks.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
2UM1AI069536-15
Application #
10056791
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Greenfield, Teri L
Project Start
2007-01-01
Project End
2027-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
15
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of California, San Diego
Department
Pediatrics
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Zhang, Gang; Luk, Brian T; Hamidy, Morcel et al. (2018) Induction of a Na+/K+-ATPase-dependent form of autophagy triggers preferential cell death of human immunodeficiency virus type-1-infected macrophages. Autophagy 14:1359-1375
Campbell, Grant R; Bruckman, Rachel S; Herns, Shayna D et al. (2018) Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication. J Biol Chem 293:5808-5820
Baker, Jason V; Sharma, Shweta; Achhra, Amit C et al. (2017) Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial. J Am Heart Assoc 6:
Garg, Ankita; Trout, Rodney; Spector, Stephen A (2017) Human Immunodeficiency Virus Type-1 Myeloid Derived Suppressor Cells Inhibit Cytomegalovirus Inflammation through Interleukin-27 and B7-H4. Sci Rep 7:44485
Bolton Moore, Carolyn; Capparelli, Edmund V; Samson, Pearl et al. (2017) CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection. AIDS 31:1129-1136
Singh, Kumud K; Qin, Min; Brummel, Sean S et al. (2016) Killer Cell Immunoglobulin-Like Receptor Alleles Alter HIV Disease in Children. PLoS One 11:e0151364
Fowler, Mary G; Qin, Min; Fiscus, Susan A et al. (2016) Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. N Engl J Med 375:1726-1737
Brummel, Sean S; Singh, Kumud K; Maihofer, Adam X et al. (2016) Associations of Genetically Determined Continental Ancestry With CD4+ Count and Plasma HIV-1 RNA Beyond Self-Reported Race and Ethnicity. J Acquir Immune Defic Syndr 71:544-50
Gupta, Amita; Montepiedra, Grace; Gupte, Akshay et al. (2016) Low Vitamin-D Levels Combined with PKP3-SIGIRR-TMEM16J Host Variants Is Associated with Tuberculosis and Death in HIV-Infected and -Exposed Infants. PLoS One 11:e0148649
Viani, Rolando M; Araneta, Maria R; Spector, Stephen A (2016) In-Country Migration and Risk Factors for HIV Acquisition among Pregnant Women in Tijuana, Mexico. J Int Assoc Provid AIDS Care 15:228-31

Showing the most recent 10 out of 26 publications